3 results on '"Bourayou N"'
Search Results
2. 705TiP Phase II trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck
3. 742P First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.